Browse CD34

Summary
SymbolCD34
NameCD34 molecule
Aliases CD34 antigen; CD antigen CD34; Hematopoietic progenitor cell antigen CD34
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF06365 CD34/Podocalyxin family
Function

Possible adhesion molecule with a role in early hematopoiesis by mediating the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells. Could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. Presents carbohydrate ligands to selectins.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001570 vasculogenesis
GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001666 response to hypoxia
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0001822 kidney development
GO:0001894 tissue homeostasis
GO:0001935 endothelial cell proliferation
GO:0003013 circulatory system process
GO:0003014 renal system process
GO:0003094 glomerular filtration
GO:0003158 endothelium development
GO:0006809 nitric oxide biosynthetic process
GO:0007160 cell-matrix adhesion
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0009266 response to temperature stimulus
GO:0009306 protein secretion
GO:0009408 response to heat
GO:0016050 vesicle organization
GO:0030193 regulation of blood coagulation
GO:0030195 negative regulation of blood coagulation
GO:0031589 cell-substrate adhesion
GO:0032102 negative regulation of response to external stimulus
GO:0032613 interleukin-10 production
GO:0032623 interleukin-2 production
GO:0032640 tumor necrosis factor production
GO:0032653 regulation of interleukin-10 production
GO:0032663 regulation of interleukin-2 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032703 negative regulation of interleukin-2 production
GO:0032720 negative regulation of tumor necrosis factor production
GO:0032733 positive regulation of interleukin-10 production
GO:0032835 glomerulus development
GO:0034605 cellular response to heat
GO:0035759 mesangial cell-matrix adhesion
GO:0035850 epithelial cell differentiation involved in kidney development
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0036301 macrophage colony-stimulating factor production
GO:0038001 paracrine signaling
GO:0042476 odontogenesis
GO:0042481 regulation of odontogenesis
GO:0042482 positive regulation of odontogenesis
GO:0044467 glial cell-derived neurotrophic factor secretion
GO:0045019 negative regulation of nitric oxide biosynthetic process
GO:0045428 regulation of nitric oxide biosynthetic process
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0046209 nitric oxide metabolic process
GO:0048514 blood vessel morphogenesis
GO:0048871 multicellular organismal homeostasis
GO:0050663 cytokine secretion
GO:0050673 epithelial cell proliferation
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050710 negative regulation of cytokine secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050819 negative regulation of coagulation
GO:0050878 regulation of body fluid levels
GO:0050900 leukocyte migration
GO:0051047 positive regulation of secretion
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051222 positive regulation of protein transport
GO:0051224 negative regulation of protein transport
GO:0060055 angiogenesis involved in wound healing
GO:0060249 anatomical structure homeostasis
GO:0060290 transdifferentiation
GO:0061005 cell differentiation involved in kidney development
GO:0061041 regulation of wound healing
GO:0061042 vascular wound healing
GO:0061045 negative regulation of wound healing
GO:0061437 renal system vasculature development
GO:0061440 kidney vasculature development
GO:0061448 connective tissue development
GO:0070482 response to oxygen levels
GO:0070970 interleukin-2 secretion
GO:0070997 neuron death
GO:0071425 hematopoietic stem cell proliferation
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0071604 transforming growth factor beta production
GO:0071611 granulocyte colony-stimulating factor production
GO:0071634 regulation of transforming growth factor beta production
GO:0071636 positive regulation of transforming growth factor beta production
GO:0071655 regulation of granulocyte colony-stimulating factor production
GO:0071657 positive regulation of granulocyte colony-stimulating factor production
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0071971 extracellular exosome assembly
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072007 mesangial cell differentiation
GO:0072008 glomerular mesangial cell differentiation
GO:0072009 nephron epithelium development
GO:0072010 glomerular epithelium development
GO:0072011 glomerular endothelium development
GO:0072012 glomerulus vasculature development
GO:0072073 kidney epithelium development
GO:0072089 stem cell proliferation
GO:0072109 glomerular mesangium development
GO:0072202 cell differentiation involved in metanephros development
GO:0072209 metanephric mesangial cell differentiation
GO:0072210 metanephric nephron development
GO:0072223 metanephric glomerular mesangium development
GO:0072224 metanephric glomerulus development
GO:0072239 metanephric glomerulus vasculature development
GO:0072254 metanephric glomerular mesangial cell differentiation
GO:0072593 reactive oxygen species metabolic process
GO:0097205 renal filtration
GO:1900034 regulation of cellular response to heat
GO:1900035 negative regulation of cellular response to heat
GO:1900037 regulation of cellular response to hypoxia
GO:1900038 negative regulation of cellular response to hypoxia
GO:1900040 regulation of interleukin-2 secretion
GO:1900041 negative regulation of interleukin-2 secretion
GO:1900046 regulation of hemostasis
GO:1900047 negative regulation of hemostasis
GO:1900166 regulation of glial cell-derived neurotrophic factor secretion
GO:1900168 positive regulation of glial cell-derived neurotrophic factor secretion
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901256 regulation of macrophage colony-stimulating factor production
GO:1901258 positive regulation of macrophage colony-stimulating factor production
GO:1901342 regulation of vasculature development
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:1903409 reactive oxygen species biosynthetic process
GO:1903426 regulation of reactive oxygen species biosynthetic process
GO:1903427 negative regulation of reactive oxygen species biosynthetic process
GO:1903531 negative regulation of secretion by cell
GO:1903532 positive regulation of secretion by cell
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903556 negative regulation of tumor necrosis factor superfamily cytokine production
GO:1904018 positive regulation of vasculature development
GO:1904238 pericyte cell differentiation
GO:1904406 negative regulation of nitric oxide metabolic process
GO:1904950 negative regulation of establishment of protein localization
GO:1904951 positive regulation of establishment of protein localization
GO:2000027 regulation of organ morphogenesis
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000378 negative regulation of reactive oxygen species metabolic process
GO:2001057 reactive nitrogen species metabolic process
GO:2001212 regulation of vasculogenesis
GO:2001214 positive regulation of vasculogenesis
Molecular Function GO:0008134 transcription factor binding
GO:0030246 carbohydrate binding
GO:0043168 anion binding
GO:0043199 sulfate binding
GO:1901681 sulfur compound binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0009925 basal plasma membrane
GO:0016323 basolateral plasma membrane
GO:0016324 apical plasma membrane
GO:0036053 glomerular endothelium fenestra
GO:0045171 intercellular bridge
GO:0045177 apical part of cell
GO:0045178 basal part of cell
GO:0046930 pore complex
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
hsa04640 Hematopoietic cell lineage
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Summary
SymbolCD34
NameCD34 molecule
Aliases CD34 antigen; CD antigen CD34; Hematopoietic progenitor cell antigen CD34
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD34 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD34 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25046660LeukemiaPromote immunityImportantly, we observed that NK cells promote cell-associated Ag cross-presentation selectively by monocytes-derived DC (Mo-DC) and CD34-derived CD11b(neg) CD141(high) DC subsets but not by myeloid CD11b(+) DC.
24923299Breast CarcinomaPromote immunity (T cell function); increase the efficacy of immunotherapyGrafts included CD34(+) cells (mean 9.7 × 10(6)/kg), Tregs (mean 2.5 × 10(6)/kg), and Tcons (mean 1.1 × 10(6)/kg).
24892261myeloid leukemiaPromote immunity (T cell function); increase the efficacy of immunotherapyResults of multivariate analysis showed that PBPC from HLA-matched siblings containing <4 × 10(6) CD34(+)/kg was associated with higher nonrelapse mortality (hazard ratio [HR], 2.03; P = .001), overall mortality (HR, 1.48; P = .008), and lower neutrophil (odds ratio [OR], .76; P = .03) and platelet (OR, .76; P = .03) recovery.
24880020acute myeloid leukemiaPromote immunity (T cell function); increase the efficacy of immunotherapyAutologous stem cell transplantation (ASCT) was performed in patients collecting ≥3 × 10(6) CD34(+)/kg and low-dose gemtuzumab ozogamicin (GO) was performed in poor mobilizers (collecting <3 × 10(6) CD34(+)/kg).
Summary
SymbolCD34
NameCD34 molecule
Aliases CD34 antigen; CD antigen CD34; Hematopoietic progenitor cell antigen CD34
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD34 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD34
NameCD34 molecule
Aliases CD34 antigen; CD antigen CD34; Hematopoietic progenitor cell antigen CD34
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD34 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5850.113
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7310.699
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4740.721
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3020.42
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4420.823
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1340.953
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3370.447
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4240.765
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1780.915
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.6030.467
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.920.342
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2090.0652
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD34 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD34
NameCD34 molecule
Aliases CD34 antigen; CD antigen CD34; Hematopoietic progenitor cell antigen CD34
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD34. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD34
NameCD34 molecule
Aliases CD34 antigen; CD antigen CD34; Hematopoietic progenitor cell antigen CD34
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD34. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD34.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD34
NameCD34 molecule
Aliases CD34 antigen; CD antigen CD34; Hematopoietic progenitor cell antigen CD34
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD34. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD34
NameCD34 molecule
Aliases CD34 antigen; CD antigen CD34; Hematopoietic progenitor cell antigen CD34
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD34 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD34
NameCD34 molecule
Aliases CD34 antigen; CD antigen CD34; Hematopoietic progenitor cell antigen CD34
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD34 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD34
NameCD34 molecule
Aliases CD34 antigen; CD antigen CD34; Hematopoietic progenitor cell antigen CD34
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD34 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.